Drug–Drug Interactions of a Novel κ-Opioid Receptor Agonist, Nalfurafine Hydrochloride, Involving the P-Glycoprotein

被引：0
|
作者：
Akihiro Ando
Shinichiro Sasago
Yoshihiro Ohzone
Yohei Miyamoto
机构：
[1] Toray Industries,Pharmaceutical Clinical Research Department
[2] Inc.,Department of Bio Research
[3] Kamakura Techno-Science,ADME & Tox. Research Institute
[4] Inc.,undefined
[5] Sekisui Medical Co.,undefined
[6] Ltd.,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2016年 / 41卷
关键词：
Digoxin; Verapamil; Sodium Dihydrogen Phosphate; Organic Modifier Content; Uremic Pruritus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：549 / 558
页数：9
相关论文
共 50 条
  • [21] Cardiovascular Ion Channel Inhibitor Drug-Drug Interactions with P-glycoprotein
    Ledwitch, Kaitlyn V.
    Roberts, Arthur G.
    AAPS JOURNAL, 2017, 19 (02): : 409 - 420
  • [22] Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein
    Keogh, JP
    Kunta, JR
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 27 (05) : 543 - 554
  • [23] Cardiovascular Ion Channel Inhibitor Drug-Drug Interactions with P-glycoprotein
    Kaitlyn V. Ledwitch
    Arthur G. Roberts
    The AAPS Journal, 2017, 19 : 409 - 420
  • [24] P-Glycoprotein Mediated Drug Interactions in Animals and Humans with Cancer
    Mealey, K. L.
    Fidel, J.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2015, 29 (01): : 1 - 6
  • [25] DRUG-INTERACTION INVOLVING P-GLYCOPROTEIN IN RELATION TO MULTIDRUG RESISTANCE
    ATASSI, G
    TASSIN, JP
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1992, 30 (11) : 526 - 527
  • [26] PXR/CYP3A4-Humanized Mice for Studying Drug-Drug Interactions Involving Intestinal P-Glycoprotein
    Holmstock, Nico
    Gonzalez, Frank J.
    Baes, Myriam
    Annaert, Pieter
    Augustijns, Patrick
    MOLECULAR PHARMACEUTICS, 2013, 10 (03) : 1056 - 1062
  • [27] Comprehensive assessment of Cucurbitacin E related hepatotoxicity and drug-drug interactions involving CYP3A and P-glycoprotein
    Lu, Jian
    Zhang, Yuanjin
    Sun, Min
    Liu, Mingyao
    Wang, Xin
    PHYTOMEDICINE, 2017, 26 : 1 - 10
  • [28] Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein
    Tachibana, T.
    Kato, M.
    Watanabe, T.
    Mitsui, T.
    Sugiyama, Y.
    XENOBIOTICA, 2009, 39 (06) : 430 - 443
  • [29] Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin
    Ling, Spencer Y.
    Huizinga, Robert B.
    Mayo, Patrick R.
    Larouche, Richard
    Freitag, Derrick G.
    Aspeslet, Launa J.
    Foster, Robert T.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (06) : 1039 - 1050
  • [30] PHARMACOLOGICAL PROPERTIES OF NALFURAFINE, A NOVEL ANTIPRURITIC AND KAPPA-OPIOID RECEPTOR AGONIST
    Nakao, Kaoru
    ACTA DERMATO-VENEREOLOGICA, 2009, 89 (06) : 706 - 706
12345